Sachiko Hirobe

ORCID: 0000-0001-8218-8809
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Advancements in Transdermal Drug Delivery
  • Dermatology and Skin Diseases
  • Toxin Mechanisms and Immunotoxins
  • Immunotherapy and Immune Responses
  • Transgenic Plants and Applications
  • Bee Products Chemical Analysis
  • CAR-T cell therapy research
  • T-cell and B-cell Immunology
  • Nanowire Synthesis and Applications
  • Contact Dermatitis and Allergies
  • Virus-based gene therapy research
  • Viral Infectious Diseases and Gene Expression in Insects
  • Skin Protection and Aging
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Nanoparticles: synthesis and applications
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer Immunotherapy and Biomarkers
  • Pharmacy and Medical Practices
  • Cardiac tumors and thrombi
  • Drug-Induced Adverse Reactions
  • Advanced Drug Delivery Systems
  • Graphene and Nanomaterials Applications
  • Heparin-Induced Thrombocytopenia and Thrombosis
  • Cardiovascular Function and Risk Factors
  • Advanced Computing and Algorithms

Osaka University
2013-2024

Osaka University Hospital
2021-2024

Mitsui & Co (Japan)
2021

Immune Regulation (United Kingdom)
2018

Osaka University of Pharmaceutical Sciences
2018

Microneedle (MN) patches are promising for transcutaneous vaccination because they enable vaccine antigens to physically penetrate the stratum corneum via low-invasive skin puncturing, and be effectively delivered antigen-presenting cells in skin. In second-generation MN patches, dissolving MNs release loaded antigen into To shorten application time clinical practice, this study aims develop novel faster-dissolving MNs. We designed two types of made from a single thickening agent,...

10.3390/pharmaceutics9030027 article EN cc-by Pharmaceutics 2017-08-03

To improve the efficacy and safety of chimeric antigen receptor (CAR)-expressing T cell therapeutics through enhanced CAR design, we analysed structural factors that affect CAR-T function. We studied effects disulphide bonding at cysteine residues glycosylation in HD on used first-generation CAR[V/28/28/3z] CAR[V/8a/8a/3z], consisting a mouse vascular endothelial growth factor 2 (VEGFR2)-specific single-chain variable fragment tandemly linked to CD28- or CD8α-derived HD, transmembrane domain...

10.3390/ijms23074056 article EN International Journal of Molecular Sciences 2022-04-06

Nanomaterials (NMs) are defined as those which have nanostructured components less than 100 nm in diameter. They widely used various fields such medicine, cosmetics, and the food industry. However, toxicological effects of NMs well understood their applications. In particular, skin is exposed to environment at all times, so easily influenced by NMs. this study, we investigated permeability properties well-dispersed amorphous silica particles with diameters ranging from 70 1000 nm, aid safe...

10.1248/bpb.b16-00258 article EN Biological and Pharmaceutical Bulletin 2016-01-01

Transcutaneous immunization (TCI) is easy to use, minimally invasive, and has excellent efficacy in vaccines against infections. We focused on toll-like receptor (TLR) ligands as applicable adjuvants for transcutaneous formulations characterized immune responses. TCI was performed using poke-and-patch methods, which puncture holes are formed with a polyglycolic acid microneedle the back skin of mice. Various TLR were applied covered an ovalbumin-loaded hydrophilic gel patch. During screening...

10.3390/pharmaceutics12030267 article EN cc-by Pharmaceutics 2020-03-15

Avelumab, durvalumab, and atezolizumab are anti-programmed death-ligand 1 (PD-L1) antibodies approved for clinical application in Japan. Despite targeting the same molecule, avelumab elicits a different frequency of infusion-related reactions (IRRs) compared with durvalumab atezolizumab, leading to differences premedication recommendations. This study aimed collect information verify relationship during IRRs characteristics antibody molecules, by investigating caused three types actual...

10.3390/clinpract14020029 article EN cc-by Clinics and Practice 2024-02-23

We are interested in promoting the development of transcutaneous immunization using microneedle technology and attempting to apply an adjuvant with improve efficacy reduce amount antigen number administrations needed. In this study, we collected basic information help elucidate mechanism responsible for activity imiquimod (IMQ), which is a ligand toll-like receptor (TLR) 7. mouse groups administered ovalbumin (OVA), OVA-specific IgG antibody titer IMQ-adjuvanted group was higher than that...

10.3390/pharmaceutics14020385 article EN cc-by Pharmaceutics 2022-02-10
Coming Soon ...